Metagenomi (NASDAQ:MGX - Get Free Report) had its target price raised by research analysts at HC Wainwright from $7.00 to $14.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's price target would indicate a potential upside of 234.13% from the company's current price.
Other research analysts have also recently issued reports about the company. Chardan Capital reissued a "buy" rating and issued a $15.00 target price on shares of Metagenomi in a research note on Wednesday, November 20th. BMO Capital Markets decreased their target price on Metagenomi from $22.00 to $17.00 and set an "outperform" rating for the company in a research note on Thursday, August 15th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, Metagenomi has a consensus rating of "Moderate Buy" and an average price target of $16.67.
Read Our Latest Stock Report on MGX
Metagenomi Stock Up 0.5 %
Shares of Metagenomi stock traded up $0.02 during trading on Tuesday, reaching $4.19. 8,537,566 shares of the company were exchanged, compared to its average volume of 541,735. Metagenomi has a twelve month low of $1.61 and a twelve month high of $12.74. The business has a 50-day moving average price of $2.02 and a 200-day moving average price of $3.31.
Institutional Trading of Metagenomi
Several institutional investors and hedge funds have recently bought and sold shares of MGX. Rhumbline Advisers bought a new stake in Metagenomi during the second quarter worth about $26,000. BNP Paribas Financial Markets increased its position in Metagenomi by 130.9% during the third quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company's stock worth $28,000 after buying an additional 7,256 shares during the last quarter. Virtu Financial LLC acquired a new position in Metagenomi during the third quarter worth approximately $33,000. XTX Topco Ltd acquired a new position in shares of Metagenomi in the second quarter valued at approximately $66,000. Finally, Green Alpha Advisors LLC acquired a new position in shares of Metagenomi in the third quarter valued at approximately $69,000.
About Metagenomi
(
Get Free Report)
Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.
Read More
Before you consider Metagenomi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metagenomi wasn't on the list.
While Metagenomi currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
